Statins may reduce cancer-related deaths in women
https://medicaldialogues.in/nephrology/news/fruits-and-vegetable-better-than-recommended-therapy-for-managing-ckd-finds-study-70709
There have been Inconclusive findings of lipid‐lowering medications (LLMs) on cancer survival benefit and require more evidence. The researchers tested the hypothesis that adherence to this drug is associated with reduced cancer‐specific mortality in a homogeneous population who had used this drug before cancer diagnosis.
Among
women with breast cancer, colorectal cancer, or melanoma, those who were taking
cholesterol-lowering medications, were less likely to die from cancer,
according to an analysis published in the British Journal of Clinical
Pharmacology.
An increasing number of preclinical and epidemiological studies are claiming
lipid‐lowering medications (LLMs)
primarily statins have anticancer properties to inhibit proliferation, activate
apoptosis, and reduce metastas.
The analysis
included 20,046,11,719 and 6,430 women in Australia who were diagnosed with
breast cancer, colorectal cancer, and melanoma, respectively, from 2003 to
2013. The women had been prescribed cholesterol-lowering medications such as
statins before their diagnosis.
The more consistently women took these medications in the year after being
diagnosed with cancer, the lower their likelihood of dying from the disease,
suggesting that the drugs may have anti-tumor effects.
"If
this inverse adherence-response relationship is confirmed, cholesterol-lowering
medications--primarily statins--could be repurposed as adjuvant therapy to
improve cancer prognosis," said co-author Jia-Li Feng, BMed, MMed, PhD, of
QIMR Berghofer Medical Research Institute.
Adherence to lipid‐lowering medication is inversely associated with decline in
cancer‐specific mortality in breast and
colorectal cancer, and melanoma. Lipophilic statins show greater reductions in
cancer‐specific mortality. The inverse
association is not altered by receiving endocrine therapy in breast cancer.
To the
best of our knowledge, this is the first study to investigate the associations
between adherence to LLM and cancer‐specific survival in 3 biologically
homogenous cohorts. These findings provide evidence of a potential antitumour
effect and emphasise the importance of improving patients'adherence for
achieving initial mortality benefit. If confirmed, clinicians could consider
LLM as an adjuvant cancer therapy to improve prognosis.
There have been Inconclusive findings of lipid‐lowering medications (LLMs) on cancer survival benefit and require more evidence. The researchers tested the hypothesis that adherence to this drug is associated with reduced cancer‐specific mortality in a homogeneous population who had used this drug before cancer diagnosis.
Among
women with breast cancer, colorectal cancer, or melanoma, those who were taking
cholesterol-lowering medications, were less likely to die from cancer,
according to an analysis published in the British Journal of Clinical
Pharmacology.
An increasing number of preclinical and epidemiological studies are claiming
lipid‐lowering medications (LLMs)
primarily statins have anticancer properties to inhibit proliferation, activate
apoptosis, and reduce metastases.
The analysis
included 20,046,11,719 and 6,430 women in Australia who were diagnosed with
breast cancer, colorectal cancer, and melanoma, respectively, from 2003 to
2013. The women had been prescribed cholesterol-lowering medications such as
statins before their diagnosis.
The more consistently women took these medications in the year after being
diagnosed with cancer, the lower their likelihood of dying from the disease,
suggesting that the drugs may have anti-tumor effects.
"If
this inverse adherence-response relationship is confirmed, cholesterol-lowering
medications--primarily statins--could be repurposed as adjuvant therapy to
improve cancer prognosis," said co-author Jia-Li Feng, BMed, MMed, PhD, of
QIMR Berghofer Medical Research Institute.
Adherence to lipid‐lowering medication is inversely associated with decline in
cancer‐specific mortality in breast and
colorectal cancer, and melanoma. Lipophilic statins show greater reductions in
cancer‐specific mortality. The inverse
association is not altered by receiving endocrine therapy in breast cancer.
To the best of our knowledge, this is the first study to investigate the
associations between adherence to LLM and cancer‐specific survival
in 3 biologically homogenous cohorts. These findings provide
evidence of a potential antitumour effect and emphasise the
importance of improving patients'adherence for achieving initial
mortality benefit. If confirmed, clinicians could consider LLM as an
adjuvant cancer therapy to improve prognosis.